Compare Global X Robotics and Artificial Intelligence ETF (BOTZ) vs GSK plc (GSK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Global X Robotics and Artificial Intelligence ETF vs GSK plc — how do they compare? Global X Robotics and Artificial Intelligence ETF trades at $36.21, while GSK plc trades at $51.21 (market cap $101.55B). The key difference: GSK plc pays a 3.5% dividend while Global X Robotics and Artificial Intelligence ETF pays none, and GSK plc is trading nearer its 52-week high, Global X Robotics and Artificial Intelligence ETF nearer its low. Which is the better fit depends on your goals.
| BOTZ | GSK | |
|---|---|---|
52-Week High | $41.63 | $61.18 |
52-Week Low | $31.99 | $36.20 |
Market Cap | — | $101.55B |
Sector | — | Health |
Enterprise Value | — | $122.16B |
Dividend Yield | — | 3.5% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BOTZ trades at $35.87, down 2.82% with a bearish technical outlook showing 16 sell signals versus 3 buy signals. The ETF faces headwinds despite positive industry sentiment around robotics and AI growth. Recent news highlights robotics as the next frontier beyond chatbots, with humanoid robots projected to become a multi-trillion dollar market. The fund's technical indicators suggest near-term pressure with key support at $35.
The robotics and AI theme offers long-term growth potential as industrial automation and physical AI gain traction, though current technical weakness and market volatility present near-term risks. Positive industry catalysts include reshoring trends and AI's expansion into physical applications, but investors face sector rotation risks and competitive ETF landscape challenges.
GSK trades at $52.29, down 0.93% with neutral technical signals. The company shows strong fundamentals with Q1 2026 EPS beating expectations at $1.24 versus $1.16 forecast. Recent FDA approvals for Utebzi and positive Jemperli trial results highlight pipeline strength. Valuation metrics appear reasonable with P/E of 13.94 and ROE of 36.42%.
GSK presents a balanced investment case with solid profitability and promising drug pipeline offset by mixed analyst sentiment and competitive pressures. The stock offers income potential with 3.46% dividend yield but faces execution risks in drug development and market competition.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Global X Robotics and Artificial Intelligence ETF
The fund invests at least 80% of its total assets in the securities of the underlying index. The underlying index is designed to provide exposure to exchange-listed companies in developed markets that are involved in the development of robotics and/or artificial intelligence. The fund is non-diversified.
Read more on BOTZ →About GSK plc
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Read more on GSK →
